193 related articles for article (PubMed ID: 10759687)
1. Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters.
Hussain FN; Ajjan RA; Riley SA
Br J Clin Pharmacol; 2000 Apr; 49(4):323-30. PubMed ID: 10759687
[TBL] [Abstract][Full Text] [Related]
2. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis.
Sandborn WJ; Hanauer SB
Aliment Pharmacol Ther; 2003 Jan; 17(1):29-42. PubMed ID: 12492730
[TBL] [Abstract][Full Text] [Related]
3. Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters.
Hussain FN; Ajjan RA; Kapur K; Moustafa M; Riley SA
Aliment Pharmacol Ther; 2001 Jan; 15(1):53-62. PubMed ID: 11136278
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetics of slow release mesalazine.
De Vos M
Clin Pharmacokinet; 2000 Aug; 39(2):85-97. PubMed ID: 10976656
[TBL] [Abstract][Full Text] [Related]
5. Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers.
Sandborn WJ; Hanauer SB; Buch A
Aliment Pharmacol Ther; 2004 May; 19(10):1089-98. PubMed ID: 15142198
[TBL] [Abstract][Full Text] [Related]
6. Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.
Prakash A; Markham A
Drugs; 1999 Mar; 57(3):383-408. PubMed ID: 10193690
[TBL] [Abstract][Full Text] [Related]
7. Mesalazine release from a pH dependent formulation: effects of omeprazole and lactulose co-administration.
Hussain FN; Ajjan RA; Moustafa M; Weir NW; Riley SA
Br J Clin Pharmacol; 1998 Aug; 46(2):173-5. PubMed ID: 9723828
[TBL] [Abstract][Full Text] [Related]
8. Intestinal metabolism and transport of 5-aminosalicylate.
Zhou SY; Fleisher D; Pao LH; Li C; Winward B; Zimmermann EM
Drug Metab Dispos; 1999 Apr; 27(4):479-85. PubMed ID: 10101143
[TBL] [Abstract][Full Text] [Related]
9. Is once-daily mesalazine equivalent to the currently used twice-daily regimen? A study performed in 30 healthy volunteers.
Gandia P; Idier I; Houin G
J Clin Pharmacol; 2007 Mar; 47(3):334-42. PubMed ID: 17322145
[TBL] [Abstract][Full Text] [Related]
10. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease.
Shale MJ; Riley SA
Aliment Pharmacol Ther; 2003 Jul; 18(2):191-8. PubMed ID: 12869079
[TBL] [Abstract][Full Text] [Related]
11. Mono- and biphasic plasma concentration-time curves of mesalazine from a 500 mg suppository in healthy male volunteers controlled by the time of defecation before dosing.
Vree TB; Dammers E; Exler PS; Maes RA
J Pharm Pharmacol; 2000 Jun; 52(6):645-52. PubMed ID: 10875540
[TBL] [Abstract][Full Text] [Related]
12. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
Clemett D; Markham A
Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042
[TBL] [Abstract][Full Text] [Related]
13. Rectal tissue, plasma and urine concentrations of mesalazine after single and multiple administrations of 500 mg suppositories to healthy volunteers and ulcerative proctitis patients.
Aumais G; Lefebvre M; Tremblay C; Bitton A; Martin F; Giard A; Madi M; Spénard J
Aliment Pharmacol Ther; 2003 Jan; 17(1):93-7. PubMed ID: 12492737
[TBL] [Abstract][Full Text] [Related]
14. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.
Kruis W; Schreiber S; Theuer D; Brandes JW; Schütz E; Howaldt S; Krakamp B; Hämling J; Mönnikes H; Koop I; Stolte M; Pallant D; Ewald U
Gut; 2001 Dec; 49(6):783-9. PubMed ID: 11709512
[TBL] [Abstract][Full Text] [Related]
15. A clinical trial on absorption and N-acetylation of oral and rectal mesalazine.
Dilger K; Trenk D; Rössle M; Cap M; Zähringer A; Wacheck V; Remmler C; Cascorbi I; Kreisel W; Novacek G
Eur J Clin Invest; 2007 Jul; 37(7):558-65. PubMed ID: 17576207
[TBL] [Abstract][Full Text] [Related]
16. Mesalazine pharmacokinetics and NAT2 phenotype.
Lück H; Kinzig M; Jetter A; Fuhr U; Sörgel F
Eur J Clin Pharmacol; 2009 Jan; 65(1):47-54. PubMed ID: 18704388
[TBL] [Abstract][Full Text] [Related]
17. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.
Christensen LA
Dan Med Bull; 2000 Feb; 47(1):20-41. PubMed ID: 10709142
[TBL] [Abstract][Full Text] [Related]
18. Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment.
Frieri G; Pimpo MT; Palumbo GC; Onori L; Viscido A; Latella G; Galletti B; Pantaleoni GC; Caprilli R
Aliment Pharmacol Ther; 1999 Nov; 13(11):1413-7. PubMed ID: 10571596
[TBL] [Abstract][Full Text] [Related]
19. Gastrointestinal spread of oral prolonged-release mesalazine microgranules (Pentasa) dosed as either tablets or sachet.
Wilding IR; Kenyon CJ; Hooper G
Aliment Pharmacol Ther; 2000 Feb; 14(2):163-9. PubMed ID: 10651656
[TBL] [Abstract][Full Text] [Related]
20. 5-aminosalicylic acid release from a new controlled-release mesalazine formulation during gastrointestinal transit in healthy volunteers.
Brunner M; Lackner E; Exler PS; Fluiter HC; Kletter K; Tschurlovits M; Dudczak R; Eichler HG; Müller M
Aliment Pharmacol Ther; 2006 Jan; 23(1):137-44. PubMed ID: 16393291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
